• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

MAP Pharmaceuticals Appoints New Vice President of Clinical and Regulatory Affairs

Posted on: Monday, 28 March 2005, 09:00 CST

MOUNTAIN VIEW, Calif., March 28 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a leading developer of novel inhaled drug products, today announced the appointment of Stephen B. Shrewsbury, M.D., to the position of Vice President, Clinical and Regulatory Affairs. In this role, Dr. Shrewsbury will be responsible for coordinating and managing all clinical and regulatory activities at MAP, including clinical program development and execution, regulatory filing preparation and submission, and quality assurance.

Dr. Shrewsbury is an experienced industry veteran who brings MAP more than 24 years of expertise in the medical field with specific focus in the areas of research, clinical development, medical affairs and commercialization. Prior to joining the company, he served as Senior Director of Clinical Development at Chiron Corporation. In this position, Dr. Shrewsbury led a 15-person team that was responsible for advancing a number of novel inhaled therapeutics into and through the clinical stages of development. This work included development of clinical programs and protocols, oversight of clinical trials, statistical data analysis, and negotiations with FDA. While at Chiron, Dr. Shrewsbury also served as co-chair of the company's biopharma-wide protocol review committee and their safety coding committee. In 2004, he was appointed to IPAC-RS Board of Directors, a pan-industry consortium responsible for ongoing dialogue with the FDA and other organizations regarding inhaled drug delivery.

Prior to his work with Chiron, Dr. Shrewsbury held the positions of director and senior clinical program head of respiratory clinical development at GlaxoSmithKline. While at GlaxoSmithKline, he played a critical role in the development of Flovent HFA by designing, initiating and directing the product's pivotal clinical program and filing the Flovent HFA NDA. This submission represented the first alternative propellant NDA reviewed and approved by FDA. In addition to his work with GlaxoSmithKline, he has also served as associate medical director for respiratory, allergy, GI and smoking cessation, as well as medical affairs team leader, at GlaxoWellcome UK.

"The addition of Stephen to the MAP team represents a significant development in our growth as a leading developer of novel inhaled drug products," said Thomas Armer, President and Chief Scientific Officer of MAP. "Stephen's extraordinary track-record with regard to clinical development, particularly in the area of respiratory care, will serve MAP well as we continue to aggressively accelerate the development of both our lead Unit Dose Budesonide product and our proprietary Tempo(TM) Inhaler platform."

A highly-regarded expert in the field of respiratory medicine, Dr. Shrewsbury is credited with more than 30 publications in leading journals such as the American Journal of Respiratory and Critical Care Medicine, British Medical Journal, European Respiratory Journal, Annals of Allergy, Asthma & Immunology and International Journal of Pharmaceutical Medicine. Furthermore, Dr. Shrewsbury is a member or fellow of several leading medical groups, including the Royal College of General Practitioners, the American College of Chest Physicians, the American Academy of Asthma, Allergy and Immunology, the American College of Asthma, Allergy and Immunology, and the Faculty of Pharmaceutical Medicine.

Dr. Shrewsbury earned a diploma in pharmaceutical medicine from the Royal College of Physician's (UK) Faculty of Pharmaceutical Medicine, a diploma of the Royal College of Obstetricians and Gynecologists (UK), and bachelors' degrees in medicine and surgery from Liverpool University. He has also held a number of medical residency positions in areas such as respiratory/pulmonary disease, primary care, and pediatrics and neonatology.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals, Inc. is a specialty pharmaceutical company developing innovative therapies and inhalation delivery platforms to treat a broad spectrum of respiratory and systemic diseases. MAP's lead product is a proprietary formulation of budesonide for the treatment of pediatric asthma. The company is also developing a series of respiratory and inhaled systemic drugs based on its Tempo(TM) Inhaler platform, including a rapid-relief treatment for migraine. Tempo is a next generation breath-actuated pMDI that automatically adjusts to different inhalation maneuvers but is exceptionally easy to use, enhancing compliance. Tempo also features a novel aerosol flow controller that ensures efficient and consistent delivery of the drug to the lungs, while minimizing oral deposition.

For more information, please visit our website at http://www.mappharma.com/.

MAP cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by MAP that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in MAP's business due to a number of factors, including: (i) we and our products face significant competition; (ii) if we do not successfully manage any growth we experience, we may experience increased expenses without corresponding revenue increases; (iii) we are dependent on third parties for supply of all the products we offer; (iv) unexpected adverse side effects or inadequate therapeutic efficacy of our products could delay or prevent product development or commercialization, or could result in recalls or product liability claims; and (v) we may not be able to identify appropriate acquisition, licensing, or co-promotion candidates in the future or to take advantage of the opportunities we identify. All forward-looking statements are qualified in their entirety by this cautionary statement and MAP undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

MAP Pharmaceuticals, Inc.

CONTACT: Thomas Armer, PhD, President and CSO of MAP Pharmaceuticals,Inc., +1-650-625-8790, tomarmer@mappharma.com; or Stephanie C. Diaz(investors), +1-415-885-2298, sdiaz@vidaLLC.com, or Tim Brons (media),+1-646-319-8981, tbrons@vidaLLC.com, both of Vida Communication, Inc. for MAPPharmaceuticals, Inc.

Web site: http://www.mappharma.com/

Source: PRNewswire

More News in this Category